Drug Profile
Varicella zoster virus vaccine - Merck & Co
Alternative Names: Provarivax; V211; Varicella zoster virus vaccine live - Merck & Co; Variped; Varivax; Varivax II; ZostavaxLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Osaka University
- Developer CSL; Merck & Co; sanofi pasteur MSD
- Class Varicella vaccines; Viruses
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Herpes zoster; Varicella zoster virus infections
Most Recent Events
- 06 Mar 2023 Registered for Varicella zoster virus infections (Prevention, In children, In adolescents, In adults) in Liechtenstein, Norway, Iceland, European Union (IM) prior to March 2023
- 06 Mar 2023 Registered for Varicella zoster virus infections (Prevention, In children, In adults, In adolescents) in USA (IM)
- 12 Apr 2021 Varicella zoster virus vaccine is still in phase III trials for Varicella zoster virus infection in Russia (NCT03843632)